HOPO 14-1

HOPO Therapeutics is pleased to announce that SRI International has commenced a Phase 1 clinical trial for HOPO 14-1, with funding from the National Institute of Allergy and Infectious Disease. The open label study will assess safety, tolerability, pharmacokinetics, and excretion in 42 healthy participants, and is being conducted at SRI’s Plymouth, Michican facility. Coverage from the BBC and from National Geographic We are thrilled to see the progression of our lead compound to into clinical development, passing a major milestone in our mission to develop novel and accessible treatments for life-threatening heavy metal toxicity. For more information about the trial, please visit https://clinicaltrials.gov/ct2/show/NCT05628961

The first-in-human Phase 1 clinical trial of the drug candidate HOPO 14-1 is now enrolling healthy participants. Questions about recruitment can be directed to clinical-trials@sri.com and full information, including eligibility requirements, can be found at https://clinicaltrials.gov/ct2/show/NCT05628961